Candela
This article was originally published in The Gray Sheet
Executive Summary
Two-for-one stock split approved by the board will be effective March 16 for shareholders of record as of Feb. 16. The aesthetic laser maker, which recently launched the 510(k)-cleared GentleYAG laser for treating unwanted leg veins and hair removal on dark and tanned skin, and the VBeam and CBeam lasers for non-invasive acne treatment, reported Jan. 27 second fiscal quarter sales of $23.9 mil., up 33%. Earnings of $2.4 mil. for the three months ended Dec. 27 compare with $0.8 mil. for the same period last year...
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.